Life Science Practice

Edgewater’s Life Science Practice is focused on companies that create value by providing critical products or services towards the development or manufacture of pharmaceuticals, biopharmaceuticals, veterinary medicines, and medical devices. The dynamic and rapidly growing pharma services sector is a target market, with a focus on companies providing pharmaceutical Fine Chemicals, Contract Development and Manufacturing Organizations (large and small molecule), and companies offering differentiated reagents and technologies to the pharma industry.

Target Industries, End Markets, or Applications

Pharma Chemicals

Chemical intermediates

Regulatory starting materials

Active pharmaceutical ingredients

Differentiated capabilities

Contract Services Organizations

CRO, CDMO, CMO

Small molecules/large molecules (proteins/antibodies; gene/cell therapy)

Development/manufacturing

Active ingredients, formulation, warehousing/storage

Analytical/assay development services

Discovery, pre-clinical, clinical, commercial

Reagents, Materials and Technologies

Chemical or biological reagents

Enabling technologies (i.e., enzymes, catalysts, biologic processes)

Functional materials (e.g., functional excipients, adjuvants)

Practice Leader: Brian Scanlan

Practice Leader:
Brian Scanlan

bscanlan@edgewatercapital.com
Office: (216) 292-3838

Brian leads Edgewater’s Life Science practice and is engaged with several portfolio companies in advisory roles spanning commercial, operational, and Board advisory. Brian has spent nearly three decades in the pharmaceutical services sector, developing and growing companies offering highly differentiated technologies and services. He is also the Founder and Managing Partner of Freedom Bioscience Partners, a consultancy firm focused on M&A and strategic business advisory to the pharmaceutical and fine chemical industries. Prior to launching Freedom, Brian served as CEO at Cambridge Major Laboratories, a global pharma contract development and manufacturing organization (CDMO) focused on active pharmaceutical ingredients, solid state chemistry, and analytical services.

Brian holds a BS in Chemistry from Northern Illinois University and an MBA from the Illinois Institute of Technology.

Relevant Portfolio Companies